Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06914245 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Personalized Care Pathways for Bowel Symptoms in Rectal Cancer Patients_contributing Factors (Treatable)

Study acronym: Treatable
StatusRecruiting
PhaseNot applicable
SponsorKU Leuven
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Dec 2027 to Dec 2028v5
  2. Primary completion date: Mar 2027 to Dec 2027v4 Show 4 more changesShow less
    • Study completion date: Jun 2027 to Dec 2027
    • Collaborators: 1 to 9
    • Study arms: 1 to 2
    • Eligibility criteria shortened, about 3 words
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 2025 to Apr 28, 2025
    • Site details revised
    v3
  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
KU Leuven
69 trials monitored
See all monitored trials
Colorectal Cancer
3,394 trials monitored
See 159 trials at risk
Colorectal cancer is the 2nd and 3rd most common cancer in respectively women and men, of which about 40% is located in the rectum. The gold standard treatment for rectal cancer (RC) is a low anterior resection combined with chemoradiotherapy. However, this treatment negatively affects various aspects of bowel function and patients' quality of life. These bowel symptoms often remain prevalent, even 12 months after RC treatment. The aim of this study is to identify the factors contributing to persistent bowel symptoms and their long-term impact on quality of life following treatment for rectal cancer, assessed 12 months after surgery or stoma closure in surgically treated patients, and 12 months after completion of neoadjuvant therapy in patients managed with active surveillance/watch-and-wait. These insights are crucial for developing an effective care approach, as they help determine when specific evaluations should be conducted and which treatments should be applied at different stages.
Trial Details
NCT Number NCT06914245
Lead Sponsor KU Leuven
Collaborators: AZ Delta, Universitair Ziekenhuis Brussel, Ziekenhuis aan de Stroom, AZ Oostende, General Hospital Groeninge, Regionaal Ziekenhuis Heilig Hart Tienen, Meander MC, Amersfoort, the Netherlands, AZORG, UZ Leuven, Leuven, Belgium
Conditions
(from sponsor)		 Rectal Cancer, LARS - Low Anterior Resection Syndrome, Active Surveillance
Related terms Low Anterior Resection Syndrome, Rectal Neoplasms
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov